Europe Newborn Screening Market – Industry Trends and Forecast to 2030

Europe Newborn Screening Market, By Test Type (Dried Blood Spot Test, Hearing Screen Test, Critical Congenital Heart Diseases (CCHD) Test), Product Type (Instruments, Reagents and Assay Kits), Application (Congenital Heart Disease, Inherited Disorders, Infectious diseases, Hearing Disorders, Other Applications), Technology (Tandem Mass Spectrometry, Hearing Screen Technology, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, Electrophoresis, DNA-Based Assays), Disease Type (Critical Congenital Heart Diseases, Newborn Hearing Loss, Sickle Cell Disease, Phenylketonuria (PKU), Cystic Fibrosis (CF), Maple Syrup Urine Disease, Others), End User (Hospital, Paediatric Clinics, Clinics) – Industry Trends and Forecast to 2030.

Europe Newborn Screening Market Analysis and Size

The increasing prevalence of newborn disorders such as congenital diseases and neonatal diseases, as well as rising healthcare budgets are propelling market growth. The Europe newborn screening market is also expected to expand as a result of technological advances in medical science and numerous diagnostic screening procedures for the early detection of disorders. Furthermore, the government and non-governmental organizations are launching initiatives to improve mother-child care, doubling the number of newborn screening programmes worldwide.

Data Bridge Market Research analyses that the newborn screening market which was USD 0.188 billion in 2022, is expected to reach USD 0.37 billion by 2030, at a CAGR of 9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Europe Newborn Screening Market Scope and Segmentation  

Market Definition

Newborn screening is a type of newborn screening procedure used to rule out potentially fatal conditions such as metabolic and genetic disorders that are not visible at birth. These tests enable health care providers to identify and treat specific disorders, allowing a child with normal development to grow up healthy.

Europe Newborn Screening Market Dynamics

Drivers

• Rising prevalence of newborn disorders

The newborn screening market is expanding rapidly as more cases of infant-related disorders are reported. With the rise in newborn diseases, many key players have raised awareness and support for the use of advanced screening instruments for early diagnosis. Hearing, metabolic, and hormonal disorders, as well as critical congenital heart diseases, are among the most common disorders in newborns. Early detection of such diseases can help doctors treat them effectively. WHO (World Health Organization) claimed in its 2020 report that children dying within the first 28 days of birth died from diseases caused by a lack of quality care at the time of birth or skilled care and treatment immediately post-birth. These are the certain factors that help the market to grow.

• Technological advancement in the field of newborn screening

Government projects supporting technological advancement in the field of newborn screening, as well as mandatory government regulations for newborn screening, are driving the growth of the newborn screening market in Germany. According to the European Commission, a collaboration project between clinics in Poland and Germany has resulted in advances in newborn screening for metabolic diseases in both countries, with the goal of potentially benefiting thousands of newborn babies each year. Countries can now diagnose more diseases thanks to this project. Furthermore, the screening labs in Germany and Poland can now detect 14 diseases that are very common in newborn babies, thanks to the purchase of new and advanced medical equipment. As a result of it, adoption for newborn screening would rise, considering the technological advancements in newborn screening techniques.

Opportunities

• High birth rates in emerging market

The high birth rate and the availability of newborn screening procedures in public hospitals indicate an increase in product and consumable demand. The  high natality rates in some countries are due to some countries, the risk of newborn diseases has increased, creating lucrative opportunities for the Europe newborn screening market.

Restraints/Challenges

• Poor healthcare facilities and infrastructure

One of the major concerns in the newborn screening market is a lack of healthcare infrastructure and qualified professionals. The coronavirus outbreak exposed several flaws in healthcare systems, even in developing countries. Furthermore, as a result of the global economic crisis, many countries' GDP has fallen, resulting in lower healthcare spending. Furthermore, device inaccuracy and low precision, combined with a scarcity of skilled professionals, are impeding market growth. Several market players, are developing new models to improve the precision and accuracy of the kits and instruments.

This newborn screening market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the newborn screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In January 2021, NIPD Genetics announced the launch of Orean, an expanded neonatal genetic screening test for newborns, infants, and children.
• In September 2020, PerkinElmer, an American global corporation, received approval for the EONIS screening assay. With the approval, the company will be able to incorporate its newborn test for SCID (severe combined immunodeficiency), SMA (spinal muscular atrophy), and XLA (X-linked agammaglobulinemia) in newborns.

Europe Newborn Screening Market Scope

The newborn screening market is segmented on the basis of test type, product type, technology, disease type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Dried Blood Spot Test
• Hearing Screen Test
• Critical Congenital Heart Diseases (CCHD) Test

 Product Type

• Instruments
• Reagents and Assay Kits

 Technology

• Tandem Mass Spectrometry
• Hearing Screen Technology
• Pulse Oximetry Screening Technology
• Immunoassays and Enzymatic Assays
• Electrophoresis, DNA-Based Assays

 Disease Type

• Critical Congenital Heart Diseases
• Newborn Hearing Loss
• Sickle Cell Disease
• Phenylketonuria (PKU)
• Cystic Fibrosis (CF)
• Maple Syrup Urine Disease
• Others

Application

• Congenital Heart Disease
• Inherited Disorders
• Metabolic Disorders
• Endocrine Disorders
• Hemoglobin Disorders
• Other Inherited Disorders
• Infectious diseases
• Hearing Disorders
• Other Applications

End User

• Hospital
• Paediatric Clinics
• Clinics

Newborn Screening Market Regional Analysis/Insights

The newborn screening market is analyzed and market size insights and trends are provided by country, test type, product type, application, technology, disease type and end user as referenced above.

The countries covered in the newborn screening market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe

France dominates the newborn screening market owing to the five congenital diseases such as phenylketonuria, cystic fibrosis, sickle cell anemia, congenital adrenal hyperplasia and congenital hypothyroidism. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The newborn screening market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for newborn screening market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the newborn screening market. The data is available for historic period 2011-2021.

Competitive Landscape and Newborn Screening Market Share Analysis

The newborn screening market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to newborn screening market.

Some of the major players operating in the newborn screening market are:

• Thermo Fisher Scientific Inc. (U.S.)
• General Electric (U.S.)
• Natus Medical Incorporated (U.S.)
• PerkinElmer, Inc. (U.S.)
• Medtronic (Ireland)
• Trivitron Healthcare (India)
• Bio-Rad Laboratories, Inc. (U.S.)
• Demant A/S (Denmark)
• Baebies, Inc. (U.S.)
• Zentech Manufacturing, Inc. (Belgium)
• Hill-Rom Services Inc. (U.S.)
• Intelligent Hearing Systems (U.S.)
• Interacoustics A/S (Denmark)
• Masimo (U.S.)
• Medtronic (Ireland)
• Otodynamics Ltd (U.K.)
• Vivosonic Inc. (Canada)